Biomarker Stratification of Outcomes of Third-Generation EGFR TKI Therapy in Patients with Previously-Treated NSCLC

Heather Wakeley1, Jonathan W. Goldman1, Shrish Gadgite2, David R. Camidge2, Karen L. Reckamp3, Sai-Hong I. Ou4, Helena A. Yu1, Benjamin Solomon4, Stephen V. Liu3, Maurice Pérol1, Nicholas F. Dupuis1, Alex nickel1, Chris Karlovich2, Mitch Raponi3, Jean-Charles Soria1, Lecia Sequist1,4, David Carbone5

1The Cancer Institute, Memorial Sloan-Kettering Cancer Center, New York, NY; United States of America, Theradex, St. Louis, Missouri, United States of America. 2M DAnderson Cancer Center, Houston, TX, United States of America. 3Division of Lung and Thoracic Oncology, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada. 4M DAnderson Cancer Center, Boston, MA, United States of America. 5The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America. 6Duke Cancer Institute, Duke University, Durham, NC, United States of America. 7The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.